Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: A nationwide study in South Korea, a country with an intermediate tuberculosis burden

International Journal of Rheumatic Diseases

Volumn 18, Issue 3, 2015, Pages 323-330

  Jung, Seung Min ^a   Ju, Ji Hyeon ^a   Park, Mi Sun ^b   Kwok, Seung Ki ^a   Park, Kyung Su ^a   Kim, Ho Youn ^a   Yim, Hyeon Woo ^b   Park, Sung Hwan ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

Ankylosing spondylitis; Rheumatoid arthritis; TNF inhibitor; Tuberculosis; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUBERCULOSTATIC AGENT; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; DATA BASE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INFECTION PREVENTION; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; RISK FACTOR; SOUTH KOREA; TUBERCULOSIS; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; FACTUAL DATABASE; IMMUNOCOMPROMIZED PATIENT; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; LATENT TUBERCULOSIS; RHEUMATIC DISEASES; RISK ASSESSMENT; TIME; YOUNG ADULT;

ADULT; ANTIRHEUMATIC AGENTS; BIOLOGICAL PRODUCTS; DATABASES, FACTUAL; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; INFLAMMATORY BOWEL DISEASES; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; PREVALENCE; REPUBLIC OF KOREA; RHEUMATIC DISEASES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84928554742     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12530     Document Type: Article

References (27)

1. Curtis JR, Patkar N, Xie A et al. (2007) Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 56, 1125-33.
2. Askling J, Fored CM, Brandt L et al. (2007) Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 66, 1339-44.
3. Bernatsky S, Habel Y, Rahme E (2010) Observational studies of infections in rheumatoid arthritis: a metaanalysis of tumor necrosis factor antagonists. J Rheumatol 37, 928-31.
4. Ehlers S (2003) Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF. Ann Rheum Dis 62(Suppl 2), ii37-42.
5. Wallis RS (2008) Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 8, 601-11.
6. Keane J, Gershon S, Wise RP et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345, 1098-104.
7. Askling J, Fored CM, Brandt L et al. (2005) Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52, 1986-92.
8. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillancereport. Arthritis Rheum 48, 2122-7.
9. Dixon WG, Hyrich KL, Watson KD et al. (2010) Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69, 522-8.
10. Tubach F, Salmon D, Ravaud P et al. (2009) Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French ResearchAxed on Tolerance of Biotherapies registry. Arthritis Rheum 60, 1884-94.
11. Winthrop KL, Baxter R, Liu L et al. (2013) Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis 72, 37-42.
12. World Health Organization (2011) Global tuberculosis control: WHO report 2011. [Cited 30 July 2014.] Available from URL: http://www.who.int/tb/publications/global_report/2011/gtbr11_full.pdf
13. Korea Centers for Disease Control and Prevention (2011) Trend of case notification rate per 100 000 by year. [Cited 30 July 2014.] Available from URL: http://www.knta.or.kr/
14. Kang YA, Lee HW, Yoon HI et al. (2005) Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 293, 2756-61.
15. Korea Food & Drug Administration (2004) Guidelines for diagnosis and treatment of latent tuberculosis infection in patients with TNF antagonist (Korean). [Cited 30 July 2014.] Available from URL: http://www.mfds.go.kr/index.do?mid=695&seq=687&cmd=v
16. Kim EM, Uhm WS, Bae SC, Yoo DH, Kim TH (2011) Incidence of tuberculosis among korean patients with ankylosing spondylitis who are taking tumor necrosis factor blockers. J Rheumatol 38, 2218-23.
17. Seong SS, Choi CB, Woo JH et al. (2007) Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 34, 706-11.
18. Miller EA, Ernst JD (2009) Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed. J Clin Invest 119, 1079-82.
19. Harris J, Keane J (2010) How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin Exp Immunol 161, 1-9.
20. Dinarello CA (2005) Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment. J Rheumatol Suppl 74, 40-7.
21. Choi CM, Kang CI, Kim DH et al. (2006) The role of TST in the diagnosis of latent tuberculosis infection among military personnel in South Korea. Int J Tuberc Lung Dis 10, 1342-6.
22. Mow WS, Abreu-Martin MT, Papadakis KA, Pitchon HE, Targan SR, Vasiliauskas EA (2004) High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2, 309-13.
23. Joint Committee for the Development of Korean Guidelines for Tuberculosis Korea Centers for Disease Control and Prevention (2011) Korean Guidelines for Tuberculosis, 1st edn. [Cited 30 July 2014.] Available from URL: http://www.lungkorea.org/thesis/file/%B0%E1%C7%D9%C1%F8%B7%E1%C1%F6%C4%A7-%C3%D6%C1%BE20110608.pdf
24. Chang B, Park HY, Jeon K et al. (2011) Interferon-γ release assay in the diagnosis of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea. Clin Rheumatol 30, 1535-41.
25. Weinblatt ME, Kremer JM, Bankhurst AD et al. (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340, 253-9.
26. Sandborn WJ, Hanauer SB, Katz S et al. (2001) Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121, 1088-94.
27. Van den Brande JM, Braat H, van den Brink GR et al. (2003) Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124, 1774-85.